28 results
424B5
NEXI
Neximmune Inc
5 Feb 24
Prospectus supplement for primary offering
4:34pm
,” “anticipate,” “estimate,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “targets,” “likely,” “will,” “would,” “could,” “should … multiple tumor-specific antigen targets on a tumor cell. Our AIM nanoparticles emulate natural dendritic cells by delivering immune-specific instructions
8-K
EX-99.1
NEXI
Neximmune Inc
10 Aug 23
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:06pm
a functional defect in the EBV response of MS patients to select antigen peptide targets, which may be a contributing factor in the pathogenesis of MS as well
8-K
EX-99.1
11b wfii3649i9g
14 Nov 22
NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update
4:11pm
8-K
EX-99.1
oewy995pqp6cl47 vs1
14 Jul 22
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers
4:15pm
424B5
imzb4 cp1
17 Jun 22
Prospectus supplement for primary offering
4:49pm
8-K
EX-99.1
eujijnydmj7b4ny8
12 May 22
NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates
4:16pm
DEF 14A
lx3ojijk2yf
3 May 22
Definitive proxy
4:16pm
8-K
EX-99.1
q2qxiqxhcod5i2 183e
17 Mar 22
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
4:15pm
8-K
2mxtfs9cqvnye2qhzk6
17 Mar 22
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
4:15pm
S-3
jgfi7a 0cmrmze6e88
9 Mar 22
Shelf registration
5:14pm
8-K
EX-99.1
ij3yr3oarjyvebv7
9 Mar 22
NexImmune Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
4:46pm